November 16, 2016 - By Pete Kolinski · 0 Comments
The stock of Spectrum Pharmaceuticals Incorporated (NASDAQ:SPPI) registered an increase of 11.59% in short interest. SPPI’s total short interest was 8.23 million shares in November as published by FINRA. Its up 11.59% from 7.38M shares, reported previously. With 1.02M shares average volume, it will take short sellers 8 days to cover their SPPI’s short positions. The short interest to Spectrum Pharmaceuticals Incorporated’s float is 14.27%. About 235,519 shares traded hands. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 38.55% since April 14, 2016 and is downtrending. It has underperformed by 43.23% the S&P500.
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $324.58 million. The Firm operates through developing and commercializing oncology and hematology drug products segment. It currently has negative earnings. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma , metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Insitutional Activity: The institutional sentiment increased to 3.84 in Q2 2016. Its up 2.68, from 1.16 in 2016Q1. The ratio increased, as 7 funds sold all Spectrum Pharmaceuticals, Inc. shares owned while 18 reduced positions. 34 funds bought stakes while 62 increased positions. They now own 106.93 million shares or 131.39% more from 46.21 million shares in 2016Q1.
Blackrock Group Limited last reported 116,590 shares in the company. State Street Corporation holds 0% or 1.94M shares in its portfolio. Barclays Public Limited Company last reported 0.01% of its portfolio in the stock. Moreover, Goldman Sachs Group has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 1.57 million shares. Parametric Associate Ltd Com has 0% invested in the company for 164,703 shares. Ladenburg Thalmann Financial has 0% invested in the company for 9,364 shares. Limited Liability last reported 0.01% of its portfolio in the stock. Quantitative Invest Mgmt Limited Liability Co holds 49,700 shares or 0.02% of its portfolio. Wells Fargo Co Mn holds 578,205 shares or 0% of its portfolio. Blackrock Institutional Tru Na holds 1.89 million shares or 0% of its portfolio. Royal Bank Of Canada accumulated 970,332 shares or 0% of the stock. Teachers Incorporated holds 1.02 million shares or 0.01% of its portfolio. Teachers Retirement Of The State Of Kentucky reported 13,500 shares or 0% of all its holdings. Teacher Retirement Systems Of Texas last reported 9,513 shares in the company. Springbok Capital Mgmt Ltd Liability accumulated 0% or 5,374 shares.
Spectrum Pharmaceuticals, Inc., incorporated on November, 18, 2002, is a biotechnology company. The Firm operates through developing and commercializing oncology and hematology drug products segment. The Firm has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. The Company’s commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The Company’s other products include SPI-2012, POZIOTINIB and EOQUIN.
Another recent and important Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news was published by Businesswire.com which published an article titled: “IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action …” on November 08, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski